Markets
Flint.Trades
@flint.tr...
Bought CTXR
Shares
down -16.1%
At 0.39, Now 0.33
Last add before going into tomorrow. Will look for an early market move and will possibly hold some into next week.
Thesis
Last add before going into tomorrow. Will look for an early market move and will possibly hold some into next week.
Go back
Flint.Trades
@flint.tr...
Bought CTXR
Shares
down -20.04%
At 0.41, Now 0.33
Positioning myself for a breakout. Last play of the day for me.
Thesis
Positioning myself for a breakout. Last play of the day for me.
Go back
Flint.Trades
@flint.tr...
Bought CTXR
Shares
down -16.31%
At 0.39, Now 0.33
Adding another decent amount here. Going to position myself for the potential break up. I like it a lot 🤝
Thesis
Adding another decent amount here. Going to position myself for the potential break up. I like it a lot 🤝
Go back
Flint.Trades
@flint.tr...
Bought CTXR
Shares
up 11.79%
At 0.34, Exited 0.38
Adding more here. Looking a bit further on the higher timeframes could actually send us to 0.65 - 0.70. Could be a massive play.
Thesis
Adding more here. Looking a bit further on the higher timeframes could actually send us to 0.65 - 0.70. Could be a massive play.
Go back
Flint.Trades
@flint.tr...
Bought CTXR
Shares
up 11.79%
At 0.34, Exited 0.38
Looking for a good bounce here.
Thesis
Looking for a good bounce here.
Go back
Tendies
@tendies
Bought CTXR
Shares
down -51.83%
At 0.82, Exited 0.4
Citius Pharmaceuticals just received FDA approval for their new immunotherapy treatment, LYMPHIR. This approval could lead to significant revenue grow...
Read
More
Thesis
Citius Pharmaceuticals just received FDA approval for their new immunotherapy treatment, LYMPHIR. This approval could lead to significant revenue growth and investor interest, making it a strong long-term investment.
Go back
Tendies
@tendies
Bought CTXR
Shares
down -51.83%
At 0.82, Exited 0.4
With the recent FDA approval for their immunotherapy treatment LYMPHIR, I believe CTXR has significant growth potential. This kind of approval can dri...
Read
More
Thesis
With the recent FDA approval for their immunotherapy treatment LYMPHIR, I believe CTXR has significant growth potential. This kind of approval can drive long-term value and solidify their presence in the pharmaceutical market.
Go back
